On 19 November 2018, orphan designation (EU/3/18/2094) was granted by the European Commission to Y-mAbs Therapeutics A/S, Denmark, for anti-GD2 monoclonal antibody 3F8 humanised (also known as naxitamab) for the treatment of neuroblastoma.
Anti-GD2 monoclonal antibody 3F8 humanised
|Disease / condition||
Treatment of neuroblastoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.